Abbott’s Hep C Architect
This article was originally published in The Gray Sheet
Executive Summary
Firm submits PMA application for an anti-hepatitis C virus test for use on the Architectanalyzer. It would be the first hepatitis assay approved for this platform in the U.S. Abbott markets a hepatitis C and two hepatitis A assays for its AxSYM platform, and the firm recently announced approval of its HBCore assay for its Prism automated blood supply testing system (1"The Gray Sheet" Oct. 31, 2005, In Brief)...